References

  1. Mocroft A, et al. Changing patterns of mortality across Europe in patients infected with HIV-1 - EuroSIDA Study Group. Lancet. 1998; 352(9142): 1725-30. This article on PubMed

  2. Ledergerber BM, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study - Swiss HIV Cohort Study. Lancet. 1999; 353(9156):863-8. This article on PubMed

  3. Edwards IR and JK Aronson. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000; 356(9237):1255-9. This article on PubMed

  4. Domingo P and F Lozano. Management of antiretroviral drug toxicity. Enfermedades Infecciosas y Microbiologia Clinica. 2011; 29(7):535-44. This article on PubMed

  5. UNAIDS. Report on the global HIV/AIDS epidemic2008: Joint United Nations Programme on HIV/AIDS

  6. WHO/Forum for collaborative HIV Research Joint Meeting, ARV drugs adverse events, case definition, grading, laboratory diagnosis and treatment monitoring, February 28-29, 2008. Geneva, Switzerland. Available on http://www.hivforum.org/index.php?option=com_content&task=view&id=59&Itemid=102. Accessed on 16/10/2011

  7. Loubiere S at al. Decentralization of HIV care in Cameroon: increased access to antiretroviral treatment and associated persistent barriers. Health policy. 2009; 92(2-3):165-73. This article on PubMed

  8. Central Technical Group of the National AIDS control Committee, ed. Cameroon National HIV/AIDS control Strategic plan. 2006 - 2010: Yaounde

  9. Modayil RR, A Harugeri, G Parthasarathi, M Ramesh, R Prasad, V Naik, and V Giriyapura. Adverse drug reactions to antiretroviral therapy (ART): an experience of spontaneous reporting and intensive monitoring from ART centre in India. Pharmacoepidemiology and drug safety. 2010; 19(3):247-55. This article on PubMed

  10. Hawkins C, C Achenbach, W Fryda, D Ngare, and R Murphy. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. Journal of acquired immune deficiency syndromes. 2007; 45(3):304-10. This article on PubMed

  11. Forna F et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. Journal of acquired immune deficiency syndromes. 2007; 44(4):456-62. This article on PubMed

  12. Wester CW et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. Journal of acquired immune deficiency syndromes. 2005; 40(3):336-43. This article on PubMed

  13. Morgello S et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Archives of neurology. 2004; 61(4):546-51. This article on PubMed

  14. Chang KH et al. Does race protect an oriental population from developing lipodystrophy in HIV-infected individuals on HAART?. The Journal of infection. 2002; 44(1):33-8. This article on PubMed

  15. Wester CW, et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. Journal of acquired immune deficiency syndromes. 2007; 46(3):318-22. This article on PubMed

  16. van Griensven J et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2007; 101(8):793-8. This article on PubMed

  17. Danel C et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. Journal of acquired immune deficiency syndromes. 2006; 42(1):29-35. This article on PubMed

  18. Ferradini L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006; 367(9519):1335-42. This article on PubMed

  19. Sow PS, et al. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. Journal of acquired immune deficiency syndromes. 2007; 44(3):262-7. This article on PubMed

  20. Moyle G et al. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clinical therapeutics. 2004; 26(1):92-7. This article on PubMed

  21. Koduri PR et al. Zidovudine-related anemia with reticulocytosis. Annals of hematology. 2003; 82(3):184-5. This article on PubMed

  22. Khalili H et al. Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients. Pharmacoepidemiology and drug safety. 2009; 18(9):848-57. This article on PubMed

  23. van Oosterhout JJ, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005 May;10(5):464-70. This article on PubMed

  24. Mehta U, et al. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. British journal of clinical pharmacology. 2008; 65(3):396-406. This article on PubMed

&